Cargando…
Efficacy of oral ferric citrate hydrate treatment for anemia caused by niraparib: a case report
BACKGROUND: Maintenance therapy using poly(adenosine diphosphate-ribose)polymerase inhibitors may have adverse events, including hematological toxicity, and may limit therapeutic potential in patients with cancer. Niraparib-induced anemia negatively impacts one’s quality of life. Its amelioration by...
Autores principales: | Kobayashi, Hiroshi, Yamada, Yuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694605/ https://www.ncbi.nlm.nih.gov/pubmed/36424618 http://dx.doi.org/10.1186/s13256-022-03666-3 |
Ejemplares similares
-
Oral Ferric Citrate Hydrate Associated With Less Oxidative Stress Than Intravenous Saccharated Ferric Oxide
por: Nakayama, Masaaki, et al.
Publicado: (2017) -
Ferritin Elevation and Improved Responsiveness to Erythropoiesis-Stimulating Agents in Patients on Ferric Citrate Hydrate
por: Yokoyama, Keitaro, et al.
Publicado: (2017) -
Ferric Citrate Hydrate as a Phosphate Binder and Risk of Aluminum Toxicity
por: Gupta, Ajay
Publicado: (2014) -
Individualized anemia management enhanced by ferric pyrophosphate citrate protocol
por: Chait, Yossi, et al.
Publicado: (2022) -
Conventional and novel impacts of ferric citrate on iron deficiency anemia and phosphorus metabolism in rats
por: IIDA, Akio, et al.
Publicado: (2020)